The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Clinical validation study results of a microRNA signature classifier lung cancer assay demonstrated that a blood-based test can significantly reduce the high false-positive rate associated high-resolution imaging, specifically with low-dose computed tomography.
A series of studies of the Oncotype DX colon cancer test were presented at the 2014 American Society of Clinical Oncology Gastrointestinal Cancer Symposium.
A study in aggressive prostate cancer confirmed that epigenetic profiling of selected genes can provide prognostic information corresponding to Gleason score.
A post-hoc analysis of results from the phase III HEAT Study of ThermoDox, a heat-activated liposomal encapsulation of doxorubicin in combination with radio frequency ablation, suggests the agent may significantly improve overall survival in primary liver cancer patients that receive RFA treatment for 45 minutes or more.
Patients with advanced kidney cancer lived an average of seven months longer if they were taking a common type of high blood pressure medication during treatment, according to an analysis of clinical trials data.
Contrary to existing understanding, long-term follow-up of patients with two types of breast tissue abnormalities suggests that both types of abnormalities have the same potential to progress to breast cancer.
A phase III study of Imbruvica in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma was stopped early following an interim analysis and at the recommendation of an independent data monitoring committee, which concluded the study demonstrated a significant difference in progression-free survival compared to ofatumumab.
A phase III trial of Abraxane extended overall survival in metastatic pancreatic cancer, with some patients surviving longer than three years, when used in combination with gemcitabine.
